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Background: Although a number of experimental studies have suggested the role of lipocalin-2 (LCN2) and matrix
metalloproteinase-9 (MMP-9) in breast cancer progression, limited numbers of epidemiological studies have
examined the relationship between the levels of lipocalin-2 and MMP-9 and breast cancer survival.
Methods: Preoperative serum levels of lipocalin-2 and MMP-9 were measured in 303 breast cancer patients and 74
healthy controls recruited between 2004 and 2007. We examined the association between lipocalin-2 and MMP-9
levels and disease-free survival (DFS) using Cox proportional hazard regression model.
Results: The serum levels of lipocalin-2 and MMP-9 were not significantly different between patients and controls
(P> 0.05). Elevated lipocalin-2 and MMP-9 levels were associated with reduced DFS of breast cancer (Ptrend = 0.029
and Ptrend = 0.063, respectively). When lipocalin-2 and MMP-9 levels were categorized based on the combined risk
score, patients with higher levels of both lipocalin-2 and MMP-9 exhibited poor DFS compared to patients with
lower levels (Ptrend = 0.004). Furthermore, these effects were profound in patients with BMI less than 25 kg/m
2
(adjusted hazard ratio (aHR), 3.17; 95% confidence intervals (CI), 1.66-6.06, Ptrend< 0.001) or lymph-node negative
breast cancer (aHR, 5.36; 95% CI, 2.18-13.2, Ptrend< 0.001).
Conclusions: Our study suggests that the elevated levels of lipocalin-2 and MMP-9 are associated with reduced
breast cancer survival, particularly in patients with lower BMI and lymph-node negative breast cancers.Background
While breast cancer incidence has increased over the
30–40 years, mortality has remained stable or has even
decreased in the last 10–15 years, probably contributed
to earlier detection and improved treatment strategy as
well [1,2]. Considering the substantial increase in breast
cancer survivors, to identify prognostic factors asso-
ciated with recurrence and survival is more important
today ever than before after primary treatment.
Although commonly available prognostic factors include
pathology criteria such as lymph-node status, tumor size,
histologic grade and estrogen receptor (ER) status, these* Correspondence: dhkang@snu.ac.kr
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reproduction in any medium, provided the orfactors do not predict accurately exact clinical outcome
probably due to heterogeneity of breast cancers. While
numerous studies support the prognostic relevance of cir-
culating tumor marker such as CA 15–3, CA 27, CA 29,
CEA and tissue based multiparameter gene expression
assays, it is not yet sufficient to support routine use in
clinical practice [3].
Lipocalin-2, also known as neutrophil gelatinase-
associated lipocalin (NGAL), is a 25 kDa secretary glyco-
protein belonging to the lipocalin superfamily to act as
transporter of small hydrophobic substances [4]. Initially
known only as an antibacterial factor of innate immunity,
lipocalin-2 has been suggested to participate in diverse
biological processes such as, inflammation, acute organ
damage, lipid metabolism, and cancer development. Par-
ticularly, lipocalin-2 has gained attention as a potential
biomarker and a modulator of several types of human
cancers, thus a potential therapeutic target as well [5].td. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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eral studies suggest possible mechanisms underlying the
role of lipocalin-2 in mammary tumor initiation and pro-
gression [6].
Human lipocalin-2 was originally isolated in the com-
plex with matrix metalloproteinase-9 (MMP-9), a zinc
dependent proteolytic enzyme involved in the degradation
of many different constituents of basement membranes
and subsequent remodeling of extracellular matrix [7,8].
In preclinical model and in clinical samples, it was
demonstrated that lipocalin-2 could protect the degrad-
ation of MMP-9 by forming the lipocalin-2/MMP-9 com-
plex, which can enhance the enzymatic activity of MMP-9
and facilitate the tumor growth through promoting its
invasion of adjacent tissues or metastasis to distal organs
[9-11]. Not only the key roles of MMP-9 in tumorigenesis
but also their characteristics of being secreted into the
blood stream have inspired many researchers to evaluate
the associations between circulating level of MMP-9 and
clinicopathological characteristics of breast cancers. How-
ever, majority of these studies were merely designed to in-
vestigate the correlation between clinical characteristics or
disease status and circulating levels of MMP-9.
Along with the previous report that the enzymatic ac-
tivity of urinary MMP-9/lipocalin-2 complex is detected
in the urine of breast cancer patients but not in healthy
control [11], several studies have suggested that circulat-
ing MMP-9, lipocalin-2 and MMP-9/lipocalin-2 complex
could serve as a diagnostic and/or a prognostic bio-
marker in a variety of diseases with different suggested
mechanisms [12-15]. In breast cancer, only one study
has reported the positive association between the serum
level of lipocalin-2/MMP-9 complex and disease status
[16]. However, no other prior studies have examined the
relationship between the circulating level of lipocalin-2
and MMP-9 and their combined effects on the prognosis
of breast cancer.
Given the findings that both lipocalin-2 and MMP-9 are
mainly secreted into the normal breast ducts and by neu-
trophils that have infiltrated into the tumor sites [17], we
hypothesized that the serum levels of lipocalin-2 and
MMP-9 might represent the aggressiveness of breast cancer
and might be an independent prognostic factor of breast
cancer survival. In the present study, we examined the asso-
ciation between preoperative serum levels of lipocalin-2
and MMP-9 and disease-free survival (DFS) and deter-
mined the potential of both proteins as noninvasive bio-
markers in predicting the recurrence of breast cancer.
Methods
Study population
A total of 1,899 histologically confirmed incident breast
cancer cases were recruited in the Seoul National
University Hospital and Asan Medical Center between2004 and 2007 [18]. Healthy women were recruited from
a general hospital to visit for a regular health check-up in
the same catchment area for breast cancer cases. After ex-
cluding the patients with history of cancer, age frequency
matched women (N=74) were selected and included in
the analysis. At the time of interview, before any adjuvant
chemotherapy and/or surgery, peripheral blood were col-
lected and processed for the DNA extraction and serum
separation. For the 925 of the patients, peripheral blood
were collected into 10-ml serum storage tubes and were
centrifuged at 3000 g for 10 minutes at room temperature.
Serum were stocked in 0.3-ml aliquots in cryovials and
stored at −80°C until the time of measurement.
After excluding the subjects with inadequate follow-up
information, about 40% (N=370) of subjects were selected.
A retrospective chart review was used to collect clinical in-
formation and pathologic features including cancer stage
based on 6th AJCC classification, tumor size, lymph-node
invasion, distant organ metastasis, histologic grade, nuclear
grade, estrogen receptor (ER) and progesterone receptor
(PR) status, nuclear grade, histological grade, surgical treat-
ment and medical adjuvant therapy (adjuvant chemother-
apy, radiation therapy, and hormone receptor therapy).
Those with prehistory of cancer, multi-cancer at diagnosis,
distant organ metastasis at diagnosis, and in situ breast can-
cer were additionally excluded. Thus, a total of 303 invasive
ductal carcinoma cancer patients diagnosed with stage
I-IIIC who underwent curative resection were included
for final analysis.
Informed consents were received from every patient
when the questionnaire was administered. The study de-
sign was approved by the Committee on Human Research
of Seoul National University Hospital (IRB No. H-0503-
144-004).
Serum lipocalin-2 and MMP-9 assays
The serum levels of proteins were determined using the
QuantikineW Human Lipocalin-2/NGAL Immunoassay
kit (R&D Systems, Minneapolis, MN, USA) and Human
MMP-9 ELISA Kit (Bender MedSystem, Vienna, Austria)
according to the manufacturer’s instruction. Reproduci-
bility within the assay was evaluated with an intra-assay
coefficient of variation of 3.7% for lipocalin-2 and 7.3%
for MMP-9, respectively. The specificity was confirmed
by testing its cross-reactivity with human recombinant
COX-2, lipocalin-1, MMP-9 and mouse recombinant
lipocain-2. No significant cross-reactivity or interference
was observed other than recombinant human MMP-9
/NGAL complex shows approximately 0.3% cross re-
activity in this assay. The minimum detectable dose
(MDD) was defined as the analyte concentration result-
ing in an absorbance significantly higher than that of the
dilution medium (mean plus 2 standard deviations
(SD)). The mean MDD of lipocalin-2 and MMP-9 was
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pendent assays).
Statistical analyses
The serum levels of lipocalin-2 and MMP-9 between cases
and controls were compared by non-parametric Wilcoxon
signed rank test and Student’s t-test. The distributions of
lipocalin-2 and MMP-9 according to demographic factors
and clinicopathological variables were compared by using
Mantel-Haenszel chi-square test for categorical variables
and Pearson correlation coefficients test for continuous
variables. Since the levels of lipocalin-2 and MMP-9 were
not normally distributed (the Kolmogorov–Smirnov test,
P< 0.10), log square transformed values were used for
correlation tests and survival analyses.
DFS was defined as the time from date of surgery to
the date of the first locoregional recurrence, first distant
metastasis, 2nd primary cancer or death from any cause.
Patients known to be alive with no evidence of disease
were censored at the last follow-up date.
Cox’s proportional hazard regression models were
used to estimate hazard ratios (HR) and 95% confidence
intervals (CI). The proportional hazard assumption of
the Cox model was examined by graphic evaluation of
Schoenfeld residual plot. The multivariate model
included TNM stage (I, IIA-IIB, and IIIA-IIIC), ER sta-
tus, and radiation therapy (yes and no). We included
BMI (< 25 kg/m2 and≥ 25 kg/m2) as well due to the sig-
nificant association between lipocalin-2 and BMI groups.
Other covariates considered but not included the final
model were age (≤ 39, 40–49, and ≥ 50), menopausal sta-
tus, lymph-node status, tumor size, histologic grade (I-II
and III), nuclear grade (I-II and III), PR status, adjuvant
chemotherapy and hormone receptor therapy. Because
these variables did not alter HRs significantly after
adjusting for other covariates (statistical significance was
set at P< 0.05) and the full model adjusted for all covari-
ates made no substantial difference to the results com-
pared to the reduced model. We conducted analysis
with lipocalin-2 and MMP-9 as continuous variables and
as categorical variables in tertiles based on the distribu-
tions of cases.
To further assess the combined effects of both
markers, we generated an equation, combined risk
score = exp [(0.054 x log square transformed values of
lipocalin-2) + (0.024 x log square transformed values of
MMP-9)], based on the linear regression model using the
coefficients of each marker determined by the multivariate
model including each marker (continuous) and adjust-
ment variables. The range of combined score was 1.092 to
14.276. The subjects were categorized into tertiles based
on the distribution of the combined score: low (1.092-
3.463), medium (3.464-4.997) and high (4.998-14.276)
score groups. Wald P values for trend were computed bytreating the tertiles or combined score groups as ordinal
variable.
Additionally, stratified analyses were performed according
to age group, menopausal status, BMI group, stage, tumor
size, lymph-node status and ER/PR status. We tested for
heterogeneity between strata by including product term of
marker and stratification variable of interest in regression
model.
To evaluate the predictive accuracy of serum bio-
markers, receiver operating characteristic (ROC)
curve and the area under the curve (AUC) were ana-
lyzed. In addition, to assess the internal validity of our
model, we used k-fold cross-validation method using the
entire dataset as both for development and validation of
the model [19].
All statistical procedures were conducted using SAS ver-
sion 9.2 (SAS Institute, Cary, NC) and STATA version
11.2 (Statacorp, College Station, TX). All P values reported
were two-sided.
Results
The baseline characteristics of 303 breast cancer cases
and 74 age and sex matched controls were described in
Additional file 1: Table S1. The distributions of age and
BMI were not different between cases and controls.
Figure 1 shows the distribution of lipocalin-2 and MMP-
9 in cases and controls. The levels of both markers were
not significantly different between groups although
the means of lipocalin-2 and MMP-9 of cases were
slightly higher than those of controls (98.8 ± 81.7 vs.
93.0 ± 29.9 ng/ml for lipocalin-2 and 70.5 ± 64.3 vs.
62.8 ± 55.1 ng/ml, respectively).
After a median follow-up of 4.2 years (range, 0.2-
5.3 years) there were 87 DFS events including 10 deaths
from any cause among all 303 patients. Table 1 summar-
ized univariate and multivariate–adjusted HRs for DFS
by patients' characteristics. Most patients were premeno-
pausal (63.3%) and had BMI less than 25 kg/m2 (75.6%).
In multivariate analysis, TNM stage, ER status and radi-
ation therapy were remained as independent and signifi-
cant prognostic factors for DFS (P< 0.05).
There was significant correlation between serum levels
of lipocalin-2 and MMP-9 (rpearson
2 = 0.267; P< 0.001).
Table 2 shows the distributions of patients’ characteris-
tics according to tertiles of lipocalin-2 and MMP-9.
Women with higher lipocalin-2 levels were more likely
to be heavier compared with women with low lipocalin-
2 levels (Ptrend = 0.054). No other significant association
was found between lipocalin-2 and MMP-9 and clinico-
pathological characteristics.
Table 3 shows the stage-, ER status-, BMI, and radi-
ation therapy-adjusted HRs for DFS by lipocalin-2 and
MMP-9 levels in overall patients. The elevated serum
levels of lipocalin-2 and MMP-9 were significantly
Figure 1 Serum levels of (a) lipocalin-2 and (b) MMP-9 depicted
as box-plots. The levels of both markers were compared between
breast cancer cases (N= 303) and age and sex matched healthy
controls (N= 74). Lines inside boxes represent the median value and
each box represents the interquartile range. Lines extend to
minimum and maximum values excluding extreme values (circles).
P-value was calculated from non-parametric Wilcoxon signed rank
test.
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ation. The adjusted HR for the 3 categories of lipocalin-
2 were 1.96 (95% CI, 1.12-3.43) for the second tertile
and 1.93 (95% CI, 1.07-3.47) for the third tertile com-
pared with first tertile as reference group (Ptrend = 0.029).
The similar but marginally significant relationship was
observed for the association between MMP-9 and DFS
(adjusted HR for third vs. first tertile 1.70; 95% CI 0.97-
2.99; Ptrend = 0.063).
Furthermore, we evaluated the combined effect of
lipocalin-2 and MMP-9 on DFS. When the patients were
classified into three groups based on the combined
scores, patients in the high score group had exhibited
significantly worse DFS compared to those belonging to
low score group (adjusted HR 2.22; 95% CI, 1.29-3.84;
Ptrend = 0.004).
The ability of combined score to predict breast cancer
survival was verified using an analysis of ROC curve(Additional file 1: Table S2). The AUC of combined score
of both markers was 0.568 (95% CI, 0.50-0.64). In
addition, the AUC fitted with the model including com-
bined score and other covariates was 0.740 (95% CI, 0.68-
0.80). Furthermore, the internal validity was evaluated
using 10-fold cross validation. The AUC of prediction
error (PE) fitted model was 0.711 (95%, 0.65-0.78) which
was slightly less than that of naïve model Figure 2.
The adverse association between combined scores
and DFS seemed to be even stronger in certain subgroups
including women with a BMI less than 25 km/m2 and
women whose tumors were lymph-node negative (Table 4).
The adjusted HR of high score group was 3.17 com-
pared with low score group (95% CI, 1.66-6.06; P< 0.001;
Ptrend< 0.001), but no significant association was
found in patients with a BMI more than 25 km/m2
(Pinteraction = 0.031). A more significant and profound
association was found in lymph-node negative patients
with an adjusted HR of 5.36 (95% CI, 2.18-13.2; P< 0.001;
Ptrend< 0.001) than in lymph-node positive patients
(Pinteraction = 0.094). However, the associations between the
score group and DFS were not different by age group,
tumor size, histologic grade, nuclear grade, and hormone
receptor status (Pinteraction> 0.10) (data not shown).
Discussion
In the present study, we found that patients with elevated
lipocalin-2 or MMP-9 levels at diagnosis had poorer DFS
than patients with low lipocalin-2 or MMP-9 levels.
Women with a high level of lipocalin-2 (> 59.03 ng/ml)
and MMP-9 (> 34.42 ng/ml) had significantly increased
risk for recurrence or death than women with a low level
of each protein. In addition, patients with both markers in
high levels showed significantly poor DFS, especially in
the women with low BMI or lymph-node negative breast
cancer.
Although Noh et al. suggested the lymphovascular in-
vasion, poorer histologic grade and higher nuclear grade
are associated with poor DFS in Korean breast cancer
cases in recently published paper [20], histologic grade
and nuclear grade were not independently associated
with DFS in our subjects. There could be several reasons
for this varied survival profile such as relatively shorter
follow-up period of our study, different baseline charac-
teristics of study population and definition of outcome
of both studies, and uncontrolled bias from method of
tumor assessment.
Several studies investigated the serum level of
lipocalin-2 and MMP-9 not only in patients with dis-
eases but also in healthy controls. The previous observa-
tional studies have shown that the mean or median
baseline value of lipoclalin-2 is highly contradictory
dependent on the study design and assay method
[21,22]. The normal range of lipocalin-2 measured
Table 1 Hazard ratios for disease-free survival of breast cancer





N % N %
F/U duration (median), days 67-1930 (1540) 67-1930 (1161)
Age, mean (SD) 46.6 (10.7) 46.5 (11.4) 0.99 (0.79-1.23) 0.897 1.00 (0.98-1.02) 0.911
< 39 81 26.7 25 28.7 1.00 1.00
40-49 108 35.6 29 33.3 0.85 (0.50-1.46) 0.557 1.21 (0.68-2.16) 0.525
50 ≤ 114 37.7 33 37.9 0.83 (0.49-1.41) 0.496 0.97 (0.54-1.76) 0.926
Menopausal statusb
Premenopausal 191 63.3 54 62.1 1.00 1.00
Postmenopausal 111 36.8 33 37.9 1.02 (0.66-1.58) 0.915 1.01 (0.62-1.64) 0.982
BMI, mean (SD) 23.3 (3.17) 23.5 (3.39)
< 25 kg/m2 229 75.6 62 71.3 1.00 1.00
≥ 25 kg/m2 74 24.4 25 28.7 1.11 (0.70-1.77) 0.665 1.10 (0.66-1.81) 0.723
TNM stage
I 115 38 18 20.7 1.00 1.00
IIA -IIB 123 40.5 36 41.4 1.89 (1.06-3.37) 0.031 1.46 (0.78-2.73) 0.242
IIIA -IIIC 65 21.5 33 37.9 3.97 (2.20-7.13) <.0001 4.41 (2.27-8.57) <.0001
Tumor size
< 2 cm 159 52.5 26 29.9 1.00 1.00
≥ 2 cm 144 47.5 61 70.1 2.78 (1.74-4.44) <.0001 2.42 (1.46-4.02) c <.0001
Lymph node status
Negative 170 56.1 40 46 1.00 1.00
Positive 133 43.9 47 54 1.54 (1.27-1.86) <.0001 1.47 (0.93-2.31) d 0.092
Histologic gradeb
I-II 160 55.4 32 39 1.00 1.00
III 129 44.6 50 61 2.11 (1.35-3.30) 0.001 1.36 (0.81-2.28) 0.248
Nuclear gradeb
I-II 145 54.6 33 39.8 1.00 1.00
III 133 45.4 50 60.2 1.96 (1.26-3.06) 0.003 1.16 (0.70-1.95) 0.564
ER status
Positive 173 57.1 36 41.4 1.00 1.00
Negative 130 42.9 51 58.6 2.40 (1.56-3.70) <.0001 2.34 (1.46-3.75) <.0001
PR status
Positive 159 52.5 33 37.9 1.00 1.00
Negative 144 47.5 54 62.1 2.19 (1.41-3,.39) 0.001 1.45 (0.79-2.65) 0.235
Adjuvant chemotherapyb
Yes 216 72.7 74 87.1 1.00 1.00
No 81 27.3 11 12.9 0.34 (0.17-0.65) 0.001 0.61 (0.26-1.41) 0.249
Radiation therapyb
Yes 184 61.7 49 57.7 1.00 1.00
No 114 38.3 36 42.4 1.26 (0.81-1.94) 0.310 2.08 (1.24-3.49) 0.006
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Table 1 Hazard ratios for disease-free survival of breast cancer (Continued)
Hormone receptor therapyb
Yes 198 66.2 41 47.7 1.00 1.00
No 101 33.8 45 52.3 2.65 (1.73-4.06) <.0001 2.03 (0.90-4.60) 0.089
a Adjusted for BMI (< 25 and ≥25 kg/m2), TNM stage (I, II, and III), ER status (positive and negative) and radiation therapy (yes and no).
b Due to missing information, total frequency is less than 303.
c Adjusted for BMI (< 25 and ≥25 kg/m2), lymph node status (yes and no), ER status (positive and negative) and radiation therapy (yes and no).
d Adjusted for BMI (< 25 and ≥25 kg/m2), tumor size (< 2 and ≥2 cm2), ER status (positive and negative) and radiation therapy (yes and no).
HR, hazard ratio; CI, confidence interval; BMI, body mass index; ER, estrogen receptor; PR, progesterone receptor.
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the range suggested by Porta et al. (47–177 ng/ml )
[23,24]. However, Choi et al. suggested the normal
range as 43.8 ± 27.8 ng/ml which is much lower than
our data (93.0 ± 29.9 ng/ml) [25].
Similarly the previous reports on the serum level of
MMP-9 in healthy controls are highly contradictory
[16,26]. Although with a small sample size, Provatopoulou
et al. demonstrated a marked increase in serum concen-
tration of lipocalin-2 and MMP-9 for women with invasive
ductal carcinoma compared with the healthy controls.
This inconsistency across the studies might be caused
mainly due to the method of sample collection (timing,
storage, and preparation etc.), detection method and
uncontrolled potential confounding factors related to
patients’ characteristics. Furthermore, several factors related
to the biochemical characteristics of each marker could
have disturbed the concentrations of serum proteins suchTable 2 The distributions of demographic and clinicophathol




Age, mean (SD) 46.5 (11.6) 47.3 (10.6) 45.9 (
Premenopausal status, % 65.0 60.4 64
BMI < 25 kg/m2, % 82.0 74.5 70
TNM stage, %
I 32.0 40.2 41
IIA –IIB 48.0 39.2 34
IIIA –IIIC 20.0 20.6 23
Tumor size < 2cm, % 46.0 53.9 57
Lymph-node negative, % 57.0 54.9 56
Histologic grade I-II, % 48.9 61.2 55
Nuclear grade I-II, % 51.6 58.0 54
ER positive, % 56.0 59.8 55
PR positive, % 51.0 54.9 51
Adjuvant chemotherapy Yes, % 75.8 66.7 75
Radiation therapy Yes, % 62.2 58.0 65
Hormone receptor therapy Yes, % 63.6 69.0 66
a Mantel-Haenszel chi-square test.
b Pearson correlation coefficients test.as the coagulation and fibrinolysis factor and leukocyte
degraulation [27]. In addition, given the sample size of our
study, the standard deviation is too large, especially for both
markers measured in cases, to obtain enough power to
compare the concentrations between cases and controls.
Thus our results should be interpreted with cautions and
need to be confirmed in larger sample size. For this reason,
we evaluated the variables based on the distribution of
cases samples rather than to define the normal range of
lipocalin-2.
In a previous study using tissue microarray containing
samples from 207 breast cancer patients, elevated ex-
pression of lipocalin-2 correlates with some indicators of
a phenotype severity including a low ER/PR expression,
a low grade of differentiation, the presence of lymph-
node metastases and a high Ki-67 proliferation index,
and overexpressed lipocalin-2 is associated with poor
DFS consistent with our results using serum [17,28,29].ogical characteristics according to tertile of lipocalin-2
MMP-9 (ng/ml)
Ptrenda t1 t2 t3 Ptrenda
772.34) (0.15-34.42) (34.42-80.36) (80.36-397.09)
9.9) 0.67b 48.2 (10.5) 44.4 (9.8) 47.1 (11.5) 0.58b
.4 0.93 53.0 72.6 64.0 0.11
.3 0.05 77.0 78.4 71.3 0.35
.6 0.59 35.0 46.1 32.7 0.72
.7 39.0 35.3 47.5
.8 26.0 18.6 19.8
.4 0.11 47.0 62.8 47.5 0.95
.4 0.94 55.0 60.8 52.5 0.72
.7 0.36 48.4 62.2 55.2 0.35
.1 0.73 52.1 57.0 54.6 0.72
.5 0.94 53.0 61.8 56.4 0.63
.5 0.95 48.0 58.8 50.5 0.73
.8 0.99 74.2 70.0 74.0 0.98
.0 0.69 67.7 60.6 57.0 0.12
.0 0.73 62.6 70.0 66.0 0.61
Table 3 Multivariate–adjusted hazard ratios for disease-free survival of lipocalin-2 and MMP-9
No. of total patients (N=303) No. of events (N=87) Adjusted HRa (95% CI) P
Lipocalin-2 continuous 1.06 (1.02-1.09) 0.001
(ng/ml) t1 100 22 1.00 (reference)
t2 102 35 1.96 (1.12-3.43) 0.018
t3 101 30 1.93 (1.07-3.47) 0.028
Ptrend 1.36 (1.03-1.79) 0.029
MMP-9 continuous 1.02 (0.99-1.06) 0.136
(ng/ml) t1 100 22 1.00 (reference)
t2 102 34 1.95 (1.12-3.39) 0.018
t3 101 31 1.70 (0.97-2.99) 0.065
Ptrend 1.28 (0.99-1.67) 0.063
Combined scoreb low 101 24 1.00 (reference)
medium 100 28 1.55 (0.88-2.74) 0.130
high 102 35 2.22 (1.29-3.84) 0.004
Ptrend 1.49 (1.14-1.95) 0.004
a Adjusted for BMI (< 25 and ≥25 kg/m2), TNM stage (I, II, and III), ER status (positive and negative) and radiation therapy (yes and no).
b The subjects were categorized into three groups based on the tertiles of combined score: low (1.092-3.463), medium (3.464-4.997) and high (4.998-14.276) score
groups.
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being detected in clinical samples of different tumor
types, especially in epithelial origin tumors, such as
esophageal [30], gastric [31], ovarian [32], pancreatic
cancers [33] with clinical outcomes are being published.
However, the precise source of serum lipocalin-2 has
remained controversial. It is plausible that the overex-
pressed lipocalin-2 in tumor tissue released into the cir-
culation may contribute to the elevated systematic level
of lipocalin-2 supported by the direct correlationFigure 2 The ROC curve of the final model. The naïve model was
fitted with Cox proportional hazard regression model using
combined score (continuous) adjusted for BMI (< 25 and ≥25 kg/
m2), TNM stage (I, II, and III), ER status (positive and negative) and
radiation therapy (yes and no). The prediction error fitted ROC was
estimated using 10-fold cross validation. Among the 303 patients,
298 subjects were used in ROC analysis since the subjects with
missing values of any covariates were excluded.between elevated serum levels of lipocalin-2 and strong
immunostaining grade in gastric tumor cells [34]. In
addition, as an acute-phase protein, lipocalin-2 may be
released into the plasma from activated neutrophils,
macrophages, and other immune cells in various inflam-
matory conditions [35,36].
Recent findings suggest possible mechanisms underlying
lipocalin-2 function in tumorigenesis, such as promoting
the epithelial-mesenchymal transition (EMT) [29], regu-
lating the iron homeostasis in cancer cells, affecting on
steroid-dependent tumor growth and modulating MMP-9
activity [6]. When lipocalin-2 is complexed with MMP-9,
there is enhancement of the active MMP-9 pool [9]. The
cooperative role between lipocalin-2 and MMP-9 in breast
cancer progression prompted us to investigate the con-
comitant presence of MMP-9 and we found the positive
correlation between lipocalin-2 and MMP-9 in serum
from breast cancer patients. Although several reports sug-
gest that elevated serum levels of MMP-9 occur in serum
and plasma of breast cancer patients [37-42], correlation
with current clinical parameters and association with
clinical outcome are still controversial mainly due to
different types of samples being assayed and sampling
procedures [27].
Furthermore, we observed the prognostic value is further
intensified in certain subgroups. We found stronger and
significant association in patients with a BMI less than
25 kg/m2. When we examined this association with a me-
dian value of BMI, the similar pattern was also observed al-
though P for interaction was marginally significant. This
finding may be partly explained by the fact that, among
patients with a BMI less than 25 kg/m2, there was
Table 4 Hazard ratios for disease-free survival and the combined risk scores of serum lipocalin-2 and MMP-9 levels
according to BMI and lymph node status
Combined score a No. of total patients (N=303) No. of events (N=87) Adjusted HRb (95% CI) P Pinteraction
BMI < 25 t1 81 17 1.00 (reference) 0.031
N=229 t2 77 20 1.74 (0.88-3.42) 0.110
t3 71 25 3.17 (1.66-6.06) <.0001
Ptrend 1.78 (1.29-2.46) <.0001
BMI ≥ 25 t1 20 13 1.00 (reference)
N =74 t2 23 15 0.92 (0.27-3.08) 0.886
t3 31 21 0.92 (0.32-2.63) 0.881
Ptrend 0.96 (0.57-1.62) 0.891
LN – t1 57 9 1.00 (reference) 0.094
N =170 t2 55 12 3.28 (1.19-9.07) 0.022
t3 58 19 5.36 (2.18-13.2) <.0001
Ptrend 2.21 (1.45-3.35) <.0001
LN + low 44 29 1.00 (reference)
N =133 medium 45 29 1.31 (0.64-2.68) 0.462
high 44 28 1.43 (0.69-2.95) 0.335
Ptrend 1.20 (0.84-1.71) 0.328
a The subjects were categorized into three groups based on the tertiles of combined score: low (1.092-3.463), medium (3.464-4.997) and high (4.998-14.276) score
groups.
b Adjusted for BMI (< 25 and ≥ 25 kg/m2), TNM stage (I, II, and III), ER status (positive and negative) and radiation therapy (Yes and No). For stratified analysis by
BMI group, the stratification variable of interest (BMI) was not included as covariate in the model.
LN –, lymph-node negative; LN +, lymph-node positive.
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alive without recurrence and patients who had recur-
rence (P< 0.05). Given that obesity at diagnosis of breast
cancer has been associated with an increased risk of recur-
rence and death [43,44], it is possible that the impact of
lipocalin-2 level and/or combined score on DFS could only
be demonstrated in the lower BMI group, with these mar-
kers being independent prognostic factors of breast cancer.
In lymph-node negative breast cancer patients, the high
score group was associated with a 5.36 fold increased risk
compared with low score group. However, because of wide
95% CIs in these categorical analyses, these results should
be interpreted with cautions. Yet the 95% CIs became nar-
rower when examining analyses between ordinal value of
risk group and DFS (HR, 2.21; 95% CI 1.45-3.35; P< 0.001).
In our study, neither lipocalin-2 nor MMP-9 level corre-
lated with lymph-node status. Assuming the cooperative
role of lipocalin-2 and MMP-9 in tumor progression, poor
prognosis associated with high levels of both markers could
be attributed to the enhanced activity of MMP-9 by
lipocalin-2 and subsequent molecular path related with
tumoral invasiveness and diffusion in lymph-node negative
status. To date, axillary lymph-node status remains the
most powerful predictor for recurrence and survival of pri-
mary breast cancer. Nevertheless, approximately one-third
of women with node negative breast cancer develop distant
metastases 10 years after local therapy [45-47]. Thus, newerprognostic factors are urgently required to identify mean-
ingful high risk subgroups within lymph-node negative
breast cancer patients who may benefit from adjuvant ther-
apy regimens. Although the hazard ratios of around 2
obtained from the combined risk score based on the overall
patients are not big enough to impact on clinical practice,
our result suggests that the combined score of both mar-
kers might have potential predictive value for metastasis
and recurrence of patients with lymph-node negative breast
cancer. However, these results are speculative and need to
be confirmed in independent and large number of subjects
to evaluate the external validity.
Our study has several limitations. We collected and
measured both markers in a single manner, thus could
not completely characterize the profiles of both markers
accompanied by treatment response and subsequent sur-
vival. In addition, due to the relatively short term follow-
up time, we could not assess the relationship between
both markers and long term survival related to mortality
of breast cancer. Thus these results must be interpreted
cautiously and need to be confirmed in large prospective
trials with serial measurements. In addition, it is worth-
while to investigate if surgical treatment of tumor results
in subsequent clearing of both markers in serum assum-
ing that the second primary cancer or recurrent breast
cancer is causative for the elevated lipocalin-2 and
MMP-9.
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In conclusion, to our knowledge, this is the only study that
has evaluated the prognostic role of preoperative serum
lipocalin-2 and combined effect of lipocalin-2 and MMP-9
in patients with operable breast cancer suggesting that the
elevated levels of lipocalin-2 and MMP-9 are associated
with reduced breast cancer survival.
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